Showing 4811-4820 of 5646 results for "".
- AcuFocus Announces Extended Diopter Range for the IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-announces-extended-diopter-range-for-the-ic-8-small-aperture-iol/2478087/AcuFocus announced that the IC-8 small aperture IOL power range now extends from +10.0 D to +30.0 D (0.50 D steps), offering eye care physicians the opportunity to provide more patients an uninterrupted extended range
- Pfizer, BioNTech Begin Phase 2/3 Coronavirus Vaccine Studyhttps://modernod.com/news/pfizer-biontech-pick-bnt162b2-to-advance-into-phase-2-3-coronavirus-vaccine-study/2478084/Pfizer and partner BioNTech said they have decided to advance the nucleoside-modified mRNA vaccine candidate BNT162b2 into phase 2/3 testing. The vaccine, to be trialed at the 30-mcg dose as part of a two-dose regimen, encodes for an optimized SARS-CoV-2 full-length spike glycoprotein, which the
- Dosing Begins in Moderna’s Late-Stage Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/dosing-begins-in-modernas-late-stage-study-of-covid-19-vaccine-candidate/2478085/Moderna announced that patient dosing started in the phase 3 COVE study of its mRNA-based vaccine candidate against the novel coronavirus, sending company shares up as much as 11.3% on Monday. The trial of mRNA-1273 is being conducted in collaboration with the US National Institute of Allergy and
- COVID-19 Vaccine Candidate Heads To Widespread Testing In U.S.https://modernod.com/news/covid-19-vaccine-candidate-heads-to-widespread-testing-in-u-s/2478083/The COVID-19 vaccine candidate made by the U.S. biotech company Moderna and developed in collaboration with the National Institutes of Health starts its final phase of testing Monday, according to an NPR
- Hanita Lenses Announces Launch of Intensity IOLhttps://modernod.com/news/hanita-lenses-announces-launch-of-intensity-iol/2478082/After 3 years of development, Israel-based Hanita Lenses announced the launch of the Intensity IOL. The Intensity is a presbyopia-correcting IOL that has been developed by employing a proprietary iterative algorithm—called the Dynamic Light Utilization (DLU) technology—for better light eff
- jCyte Announces Phase 2b Results of jCell Therapy in Retinitis Pigmentosahttps://modernod.com/news/jcyte-announces-phase-2b-results-of-jcell-therapy-in-retinitis-pigmentosa/2478078/jCyte Inc. announced promising results from a phase 2b clinical trial of jCell in retinitis pigmentosa (RP), irrespective of genetic subtype. jCell is a first-in-class investigational treatment for RP which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. In addi
- Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 Phase 2 Clinical Trial in Patients with Macular Edema Due to RVOhttps://modernod.com/news/aerie-pharmaceuticals-reports-positive-topline-results-for-ar-1105-phase-2-clinical-trial-in-patients-with-macular-edema-due-to-rvo/2478079/Aerie Pharmaceuticals reported positive topline results for the company’s phase 2 clinical trial evaluating AR-1105 (dexamethasone intravitreal implant) in patients with macular edema associated with retinal vein occlusion. AR-1105 Phase 2 Highlights
- Algorithm Compares Risk of Cancelled Ophthalmology Appointments Against COVID-19https://modernod.com/news/algorithm-compares-risk-of-cancelled-ophthalmology-appointments-against-covid-19/2478075/The COVID-19 pandemic has forced many ophthalmologists across the US to cancel potentially necessary eye examinations with patients since March. A team, led by Nikhil K. Bommakanti, MD, W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, developed a f
- Pepcid As a Coronavirus Remedy? Trump’s $21-Million Gamble Fizzledhttps://modernod.com/news/pepcid-as-a-coronavirus-remedy-trumps-21-million-gamble-fizzled/2478070/As the coronavirus began its deadly march through the world, two well-respected American doctors identified a possible but seemingly unlikely remedy: Pepcid, the heartburn medication found on drugstore shelves everywhere, according to an Associated
- Moderna Loses US Patent Challenge That Could Affect COVID-19 Vaccinehttps://modernod.com/news/moderna-loses-us-patent-challenge-that-could-affect-covid-19-vaccine/2478072/Shares in Moderna fell as much as 10% Thursday after the company failed in an attempt to invalidate a US patent on vaccine technology held by Arbutus Biopharma. SVB Leerink analyst Mani Foroohar suggested the decision by an administrative court run by the US Patent and Trademark Office opens the